(Q37971864)

26 August 2017

The role of non-HDL cholesterol in risk stratification for coronary artery disease (English)

1 reference

26 August 2017

3

John J P Kastelein

1 reference

26 August 2017

Jamal S Rana

1

1 reference

26 August 2017

S Matthijs Boekholdt

series ordinal

2

1 reference

26 August 2017

Prediman K Shah

series ordinal

4

1 reference

26 August 2017

language of work or name

1 reference

1 April 2012

1 reference

Current Atherosclerosis Reports

26 August 2017

1 reference

26 August 2017

14

1 reference

26 August 2017

2

1 reference

26 August 2017

130-134

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-011-0224-x

26 August 2017

0 references

cites work

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

Are you targeting non-high-density lipoprotein cholesterol?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

Major lipids, apolipoproteins, and risk of vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

To B or not to B: is non-high-density lipoprotein cholesterol an adequate surrogate for apolipoprotein B?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

Clinical Utility of Different Lipid Measures for Prediction of Coronary Heart Disease in Men and Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0224-X

COMPARISON OF SERUM LIPIDS IN THE PREDICTION OF CORONARY HEART DISEASE. FRAMINGHAM STUDY INDICATES THAT CHOLESTEROL LEVEL AND BLOOD PRESSURE ARE MAJOR FACTORS IN CORONARY HEART DISEASE; EFFECT OF OBESITY AND CIGARETTE SMOKING ALSO NOTED

21 January 2018

1 reference

12 December 2020

Another step forward in refining risk stratification: moving past low-density lipoprotein cholesterol

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease

1 reference

12 December 2020

A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk

1 reference

12 December 2020

10.1007/S11883-011-0224-X

Identifiers

DOI

1 reference

26 August 2017

1 reference